Heart Failure Market to Soar to $11.8 Billion by 2025 as Effective New Drugs Become Available

Wednesday, June 1, 2016 Drug News
Email Print This Page Comment bookmark
Font : A-A+

The heart failure market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, representing a compound annual growth rate of 13.7%, according to research and consulting firm GlobalData.

The company’s latest report* states that the key drivers of this substantial growth, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be the launch of Novartis’ first-in-class drug, Entresto, and several acute heart failure add-on therapies, as well as an increase in the global prevalence of chronic heart failure.

Elizabeth Hamson, Ph.D., GlobalData’s Analyst covering Cardiovascular and Metabolic Disorders, explains: “Novartis’ Entresto is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNi), which was launched in the US in 2015 and the five European countries in 2016, and is set for release in Japan by 2020. The drug has raised the benchmark for efficacious chronic heart failure therapy, although uptake has been slow.

“Entresto has struggled to penetrate the chronic heart failure market, achieving dismal sales in the US since its launch in July 2015. GlobalData has identified high pricing and the general reluctance of cardiologists and physicians to adopt new therapies as the main barriers to the uptake of this drug. Despite this, it is expected that Entresto will begin to dominate the global heart failure space, particularly after its label expansion to heart failure with preserved ejection fraction, which is expected to occur in 2020, making it the strongest driver of market growth.”

Despite these significant advances for chronic heart failure, particularly with reduced ejection fraction, there have been no advances in the treatment of acute heart failure for the past two decades. However, two drugs currently undergoing Phase III evaluation for the treatment of acute heart failure have the potential to shape how this condition is treated.

Hamson continues: “Cardiorentis’ ularitide and Novartis’ serelaxin represent novel and exciting treatment options for acute heart failure. Both are recombinant forms of human proteins that are intended to be used on top of the current standard-of-care for acute heart failure, intravenous administered loop diuretics.

“While the heart failure market will be invigorated by exciting new therapies over the forecast period, there will remain a major unmet need in the lack of a therapy which can reverse disease progression, rather than merely slowing it down. In this way, GlobalData believes that the scope for the development of even better and more exciting heart failure drugs is still very broad.”

*PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2025

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store